IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) is a modified, long-acting analogue of natural IGF-1 that sits at the center of muscle-building peptide discussion. Unlike native IGF-1, which is cleared from the blood in minutes, IGF-1 LR3 stays active for roughly a full day.The peptide slips past the binding proteins that normally switch IGF-1 off. That combination is why it is one of the most researched, most debated, and most frequently misdosed compounds in the peptide world.
Educational information only. IGF-1 LR3 is sold strictly as a research chemical and is not approved by the FDA for human use. Nothing here is medical advice, a protocol to follow, or a recommendation to obtain or use it. IGF-1 is mitogenic (it drives cell growth) and carries genuine risks discussed below. Always consult a licensed healthcare professional.
Jump to a section
What Is IGF-1 LR3?
IGF-1 LR3 is a synthetic, 83-amino-acid version of insulin-like growth factor 1, the natural hormone that carries out many of growth hormone’s muscle-building effects. It is built from the native 70-amino-acid IGF-1 with two changes: the amino acid at position 3 is swapped from glutamic acid to arginine (the “R3”), and a 13-amino-acid chain is added to one end (the “Long”). Those two modifications reduce the molecule’s binding to IGF binding proteins (IGFBPs) by roughly a thousand-fold.
That matters because in the body, roughly 98% of natural IGF-1 is locked up by binding proteins (mainly IGFBP-3) that keep it inactive and clear it within about 15 minutes. Because IGF-1 LR3 largely escapes those binding proteins, almost all of an injected dose stays free and receptor-available, and its half-life extends to roughly 20 to 30 hours. It is also about three times more potent than native IGF-1 at the receptor. The practical result: one daily injection can sustain IGF-1 receptor activation around the clock, which is the entire appeal for muscle research.
Native IGF-1 itself does have an approved medical form — mecasermin, sold as Increlex, is FDA-approved for severe primary IGF-1 deficiency (a rare growth disorder). IGF-1 LR3 is a different, modified molecule and is not approved for any use in humans; it exists in the market purely as a research chemical.
How IGF-1 LR3 Builds Muscle
IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a tyrosine-kinase receptor found on muscle cells and many other tissues. When it binds, it switches on two major signaling pathways that together drive muscle growth:
The PI3K/Akt/mTOR pathway. This is the master switch for muscle protein synthesis — the process of building new muscle proteins. Activating it tells the muscle to build, and IGF-1 LR3 is a direct, potent activator. This same pathway also drives glucose uptake into cells (through GLUT4 translocation), which is the source of both its muscle-feeding benefit and its hypoglycemia risk.
The MAPK/ERK pathway. This drives cell proliferation and differentiation, including the activation of satellite cells — the stem-like cells that fuse into existing muscle fibers, add new nuclei, and in theory allow muscle to grow beyond its normal ceiling (a process called hyperplasia). IGF-1 LR3 is considered one of the stronger satellite-cell activators discussed in the peptide space.
Nutrient partitioning. Because IGF-1 LR3 has insulin-like effects on nutrient uptake, it pushes more glucose and amino acids into muscle tissue. In practice, this means more of the food you eat is directed toward muscle — the upside — while blood sugar can drop, which is the risk to manage.
A note on the evidence: most of what is known about IGF-1 LR3 and muscle comes from cell and animal research, and the results are not uniform. A 2025 study in growth-restricted fetal sheep, for example, found IGF-1 LR3 did not promote growth in that model. The mechanisms are real, but the human muscle-building evidence is largely extrapolated, not proven in controlled human trials.
What Is IGF-1 LR3 Used For?
In laboratory research, IGF-1 LR3 is used mainly as a tool to sustain IGF-1 receptor activation in cell cultures — its resistance to binding proteins makes it useful for studying growth signaling. In the bodybuilding and biohacking communities, it is used (off-label and unapproved) for several stated goals:
- Lean muscle growth and recomposition — the primary reason people discuss it, based on its direct stimulation of muscle protein synthesis.
- Enhanced recovery — users report faster recovery between hard training sessions.
- Nutrient partitioning — directing more calories toward muscle rather than fat, particularly around training.
- Muscle “fullness” and pumps — a commonly reported subjective effect, partly from the insulin-like and glycogen effects.
It is worth being clear: these are the stated uses within a community that treats it as a performance enhancer. None are FDA-approved indications, and the World Anti-Doping Agency prohibits IGF-1 (and growth hormone) in sport. Anyone drug-tested for competition should treat it as a banned substance.
IGF-1 LR3 Dosage
Dosing figures below reflect the ranges most commonly reported in research discussion and community protocols. They are not a prescription, and because IGF-1 LR3 is unapproved, no official human dose exists. The consistent theme across sources is to start low, assess how your body responds (especially blood sugar), and avoid chasing large doses.
Starting range: commonly cited around 20–30 mcg per day, used for the first one to two weeks to gauge tolerance and blood-glucose response before any increase.
Working range: most community protocols settle around 30–50 mcg per day. Reports suggest the risk-to-benefit balance worsens above roughly 50 mcg without clear evidence of proportionally greater results.
Higher doses (50–100 mcg): discussed but widely considered to add risk (especially hypoglycemia and the theoretical growth concerns below) faster than benefit.
Because these are microgram doses drawn from a reconstituted vial, measuring accurately is essential — a small error is a large percentage of the dose. Our peptide reconstitution calculator converts your vial size, bacteriostatic water, and target dose into exact units to draw on an insulin syringe.
Disclaimer: These ranges describe what is reported in the community, not a safe or recommended dose. There is no established safe human dose for IGF-1 LR3. Do not treat these numbers as guidance.
Best Time to Take IGF-1 LR3
The most commonly reported timing is post-workout. The reasoning: training increases IGF-1 receptor expression and satellite-cell sensitivity in the worked muscle, so dosing into that window is thought to maximize the signal. On non-training days, some protocols move the dose to pre-bed, though the post-workout dose on training days is treated as the primary application.
On the “before or after workout” question that comes up constantly: community consensus leans firmly toward after. Dosing post-workout also helps with the hypoglycemia risk, because muscle glucose uptake is naturally elevated after training, which blunts the blood-sugar drop. Because IGF-1 LR3 has a 20–30 hour half-life, the exact minute of dosing matters less than people assume — levels stay elevated for a long time regardless — but the post-workout habit remains the standard.
IGF-1 LR3 Cycle Structure
This is the part most people get wrong. IGF-1 LR3 is not run continuously. The reason is receptor desensitization: sustained, uninterrupted exposure gradually reduces IGF-1 receptor density, so the compound quietly stops working while you keep dosing (and paying for it). Cycling is how the community works around that.
| Approach | Commonly Reported Structure |
|---|---|
| Standard | 3–4 weeks on, then at least 4 weeks off |
| “21-day cycle” | 21 days on, 4 weeks off |
| Conservative | 2 weeks on, 4 weeks off |
The off-weeks exist to let receptor density recover. Many users report their strongest response in the first three weeks of a cycle, precisely because receptor sensitivity is highest then — which is the argument for keeping “on” periods short rather than extending them.
IGF-1 LR3 Stacks
IGF-1 LR3 is frequently discussed alongside other compounds. The combinations below are described as they appear in community protocols; pairing unapproved research chemicals compounds the unknowns and the risks, and none of this is a recommendation to combine anything.
IGF-1 LR3 + CJC-1295 + Ipamorelin
One of the most cited recomposition stacks. CJC-1295 with ipamorelin raises the body’s own growth hormone, which in turn raises natural IGF-1 production; adding IGF-1 LR3 layers direct receptor stimulation on top. Timing is kept separate — the GH secretagogues fasted (morning or pre-bed), IGF-1 LR3 post-workout — so the LR3 lands during peak muscle sensitivity. See our CJC-1295 dosage calculator and ipamorelin dosage calculator.
IGF-1 LR3 + BPC-157
BPC-157 is added mainly for recovery and its reported support of growth-hormone-receptor expression, which may improve the environment IGF-1 LR3 acts in. Its practical value is letting you train hard enough, and recover well enough, to actually benefit. See our BPC-157 dosage calculator.
IGF-1 LR3 + PEG-MGF
PEG-MGF is a muscle-specific splice variant of IGF-1 that activates satellite cells early, while IGF-1 LR3 drives the later protein-synthesis phase. Protocols describe a two-wave approach: PEG-MGF soon after training, IGF-1 LR3 several hours later.
IGF-1 LR3 + Testosterone or Other Anabolics
In enhanced-bodybuilding circles, IGF-1 LR3 is often discussed as an add-on to a testosterone or anabolic-steroid base rather than as a standalone. The logic offered is that the anabolic base builds the muscle while IGF-1 LR3 contributes hyperplasia and nutrient partitioning. This is the highest-risk category of use, combining multiple unregulated and prohibited substances, and it sits well outside anything defensible or advisable.
Disclaimer: Stacking multiple research chemicals multiplies unknown risks and has no safety data. This section documents what is discussed, not a protocol to follow.
Injection Route and Sites
Subcutaneous (subQ) injection — into the fat layer, commonly the lower abdomen — is the most practical and most reported route. Some protocols use intramuscular “site injection” directly into the trained muscle, on the theory that local receptor stimulation encourages localized growth; the evidence for a real site-specific advantage is weak and disputed, and subQ is considered reliable. As with any injection, rotating sites avoids irritation, lumps, and scar tissue, and standard sterile technique (clean hands, alcohol-swabbed vial and skin, a fresh needle each time) is essential to avoid infection.
IGF-1 LR3 vs HGH: Which Is Better?
This is one of the most common comparisons, and the honest answer is that they are not really interchangeable — they act at different points of the same axis. Growth hormone (HGH) works largely by signaling the liver and other tissues to produce IGF-1, which then does much of the downstream muscle work. So HGH is the upstream signal, and IGF-1 is a major part of its downstream effect. IGF-1 LR3 skips the upstream step and stimulates the IGF-1 receptor directly.
In practice, the communities that discuss both describe HGH as having broader, slower, whole-body effects (fat loss, connective tissue, sleep, skin) built up over months, while IGF-1 LR3 is described as more targeted at muscle-cell growth and faster-acting but shorter-lived in its cycle. Neither is “better” in a general sense: HGH is a much larger commitment (cost, long timelines, its own risk profile), while IGF-1 LR3 is more acute and carries the specific hypoglycemia and mitogenic concerns detailed below. Both are prohibited in sport and neither is approved for muscle building.
IGF-1 LR3 Results and Timeline
Reported timelines vary, but the pattern people describe is fairly consistent. Improved pumps and faster recovery are often noticed within the first week. Visible changes in muscle fullness typically emerge around weeks two to three of a cycle. The larger point most experienced users make is that IGF-1 LR3’s benefit accumulates across several properly cycled runs rather than from a single cycle, and that it only works on top of a real foundation — adequate training, protein, and sleep. Without that base, results are minimal regardless of dose. It is also worth repeating that these are subjective community reports, not controlled trial outcomes; the objective human evidence for meaningful muscle gain remains thin.
Users on IGF-1 LR3: What Do the Forums Say?
Read this as anecdote, not evidence. The following summarizes recurring themes from bodybuilding forums (such as r/PEDs, r/Peptides, and boards like MESO-Rx and older AnabolicMinds threads). These are unverified personal reports from anonymous users, not clinical data, and they frequently contradict each other. They are included so you understand the real-world conversation, not as anything to act on.
“It’s not magic on its own.” The single most common experienced-user sentiment is that IGF-1 LR3 is not a standalone mass builder. Veterans repeatedly push back on newer users expecting dramatic gains, arguing the effect is subtle unless it sits on top of a serious training base, high protein intake, and often other compounds. Disappointed first-cycle reports are usually met with “your diet and training weren’t dialed in.”
Pumps and fullness are the most agreed-on effect. Where users converge is the subjective sense of fuller muscles, better pumps, and improved recovery during a cycle. Many describe this as the clearest sign it is “working,” though skeptics counter that it is partly a glycogen and water effect rather than new tissue.
Deep skepticism about product quality. A recurring and important theme is doubt over whether vials actually contain real, correctly-dosed IGF-1 LR3. Because it is a fragile peptide sold on the gray market, forum veterans obsess over third-party testing, storage, and reconstitution, and many argue a large share of “it didn’t work” reports are really under-dosed or degraded product. This is one of the most consistent warnings across boards.
Hypoglycemia stories are common. Users frequently share experiences of shakiness, sweating, and light-headedness, especially when dosing fasted or higher, and the standard forum advice is to eat carbs around the dose and never inject on an empty stomach. These first-hand accounts line up with the known pharmacology.
Ongoing debate over dosing and site injection. There is no forum consensus on optimal dose or on whether intramuscular “site injection” does anything beyond subQ. Threads on this run for pages, with experienced users often concluding the differences are marginal and overshadowed by diet, training, and product quality.
The long-term-safety minority. A smaller but vocal group repeatedly raises the cancer/mitogenic concern, cautioning against long-term or high-dose use and against running it with a family cancer history. These voices are often the most experienced on the boards, and their caution is worth more weight than the hype.
Disclaimer: Forum reports are anecdotal, unverifiable, and often influenced by other compounds users are taking. They are not a substitute for medical evidence or professional guidance.
Risks and Safety
Hypoglycemia (low blood sugar) is the main acute risk, from IGF-1 LR3’s insulin-like activity. Symptoms — shakiness, lightheadedness, sweating, mental fog, and in severe cases fainting — tend to appear 30 to 90 minutes after a dose. The commonly described precautions are to dose post-workout rather than fasted, keep fast-acting carbohydrates on hand, start at a low dose to gauge the response, and consider a glucose monitor for the first cycle. If you also use GLP-1 drugs (semaglutide, tirzepatide, retatrutide), the appetite suppression can mask hunger cues that would otherwise warn you of a glucose drop.
Non-selective growth is the serious long-term concern. IGF-1 tells cells to grow, and it does not distinguish muscle cells from other cells. Chronically elevated IGF-1 is associated in the medical literature with increased risk of several cancers, which is why anyone with a personal or family cancer history, or elevated markers, is repeatedly warned away from it. It can also promote growth of organs and, in theory, of existing undiagnosed tumors. This is not a fringe worry — it is the central reason IGF-1 analogues are not used casually in medicine.
Other reported concerns include acromegaly-like effects (growth of hands, feet, and facial features) with prolonged use, joint pain, and the general risks of gray-market injectables: contamination, incorrect dosing, and unsterile product.
Who it is considered inappropriate for: beginners without an established training and nutrition base, anyone with a cancer history or elevated cancer markers, anyone pregnant or breastfeeding, and anyone unable to monitor blood glucose. Because it is unapproved, purity and dosing accuracy also vary between sources, adding another layer of risk.
Disclaimer: This is not a complete list of risks, and IGF-1 LR3 has not been studied for long-term safety in humans. Only a qualified physician can assess whether any risk applies to you.
IGF-1 LR3 Frequently Asked Questions
What is IGF-1 LR3 used for?
In research it is used as a tool to sustain IGF-1 receptor activation in cell and animal studies. In the bodybuilding community it is used off-label and unapproved for lean muscle growth, body recomposition, faster recovery, and nutrient partitioning. None of these are FDA-approved uses, and IGF-1 is banned in competitive sport.
What does IGF-1 do to the body?
IGF-1 is a natural hormone that mediates many of growth hormone’s effects. It binds the IGF-1 receptor and activates pathways that increase protein synthesis, cell growth and proliferation, and glucose and amino-acid uptake into cells. It plays a central role in childhood growth and in tissue maintenance and repair throughout life — and because it drives cell growth broadly, chronically high levels are linked to increased cancer risk.
Which is better, HGH or IGF-1 LR3?
Neither is universally “better” — they act at different points of the same axis. HGH signals the body to produce its own IGF-1 and has broad, gradual, whole-body effects; IGF-1 LR3 stimulates the IGF-1 receptor directly and is more targeted and faster-acting but shorter in its cycle. HGH is a bigger commitment in cost and time; IGF-1 LR3 carries specific hypoglycemia and growth risks. Both are unapproved for muscle building and banned in sport.
Does IGF-1 LR3 make you stronger?
Users often report better pumps, recovery, and muscle fullness, which can support strength training indirectly, and its effect on muscle protein synthesis could in theory contribute to strength over time. However, there is no solid controlled human evidence that IGF-1 LR3 directly increases maximal strength, and reported effects are subjective and confounded by training and other compounds. It is not a reliable, proven strength enhancer.
Does IGF-1 really build muscle?
IGF-1 is genuinely anabolic at the cellular level — it stimulates muscle protein synthesis and satellite-cell activity, and animal models overexpressing IGF-1 show increased muscle. But translating that into meaningful muscle gain from injected IGF-1 LR3 in healthy humans is not well proven; some research (including a 2025 fetal-sheep study) found no growth effect in its model. Community reports are mixed and depend heavily on training, diet, and product quality. The honest summary: plausible mechanism, weak human evidence.
Is IGF-1 a steroid?
No. IGF-1 is a peptide hormone (a chain of amino acids), while anabolic steroids are a different chemical class derived from cholesterol. They are often discussed together because both are anabolic and both are used and banned in sport, but they work through completely different receptors and mechanisms. IGF-1 acts on the IGF-1 receptor; steroids act on the androgen receptor.
Does IGF-1 increase testosterone?
IGF-1 is not a direct testosterone booster, and the main relationship actually runs the other way: in men, testosterone supports growth hormone and IGF-1 levels, and testosterone replacement can raise IGF-1. There is some interplay in the reproductive axis, but taking IGF-1 LR3 should not be expected to meaningfully raise testosterone. They are separate hormones on separate pathways.
What is the typical IGF-1 LR3 dosage?
Community protocols most often cite a starting range of 20–30 mcg per day and a working range of 30–50 mcg per day, taken post-workout. Doses above roughly 50 mcg are widely viewed as adding risk faster than benefit. No official human dose exists because IGF-1 LR3 is not FDA-approved, so these figures are community reports, not guidance.
What is the best time to take IGF-1 LR3?
Post-workout is the most commonly reported timing, because training raises IGF-1 receptor sensitivity and elevated post-exercise glucose uptake reduces the risk of a blood-sugar crash. On rest days some protocols shift to pre-bed. Given its 20–30 hour half-life, the exact timing matters less than avoiding fasted dosing.
How long should an IGF-1 LR3 cycle be?
The most common structure is 3–4 weeks on followed by at least 4 weeks off, with some using a 21-day cycle and conservative users running 2 weeks on. The off period lets IGF-1 receptor density recover, since continuous use causes desensitization and diminishing returns.
What is the half-life of IGF-1 LR3?
IGF-1 LR3 has a half-life of roughly 20 to 30 hours, compared with about 12 to 15 minutes for native IGF-1. The extended half-life comes from its greatly reduced binding to IGF binding proteins, which keeps nearly all of a dose free and active, and is why it is dosed once daily.
What are IGF-1 side effects?
The main acute side effect is hypoglycemia (low blood sugar) from its insulin-like activity, causing shakiness, sweating, and light-headedness. Other reported concerns include joint pain, organ growth and acromegaly-like changes with prolonged use, and — most seriously — an association between chronically elevated IGF-1 and increased cancer risk. Gray-market products add risks of contamination and incorrect dosing.
Is IGF-1 LR3 safe to use?
IGF-1 LR3 is not FDA-approved and has not been studied for long-term safety in humans, so it cannot be called safe. Its short-term hypoglycemia risk is manageable with care, but the long-term mitogenic (cancer-risk) concern is real and is the reason it is considered inappropriate for anyone with a cancer history. Anyone considering it should speak with a licensed healthcare professional first.
Where do you inject IGF-1 LR3?
The most practical route is subcutaneous injection into the fat layer, commonly the lower abdomen. Some protocols use intramuscular “site injection” into the trained muscle for a theoretical local effect, though evidence for a real advantage is weak. Rotate sites and use sterile technique to avoid irritation and infection.
What is the difference between IGF-1 LR3 and IGF-1 DES?
IGF-1 DES is a shortened, highly potent form with a very short half-life (around 20–30 minutes), typically discussed for localized site injections. IGF-1 LR3 is the long-acting systemic form with a 20–30 hour half-life. They are used for different purposes — DES for a brief local burst, LR3 for sustained whole-body receptor activation.
Resources & Scientific References
For readers who want to go deeper, these are authoritative primary and reference sources on IGF-1, IGF-1 LR3, and the growth-hormone axis. We link only to research, medical, and reference sources — not to vendors.
Peer-Reviewed Research (PubMed / PMC)
- Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. — a thorough review of how GH and IGF-1 affect muscle, including their use as performance enhancers.
- IGF-1 signaling and IGF binding proteins (PMC). — the IGF-1 receptor, PI3K/Akt and MAPK/ERK pathways, and how IGFBPs regulate IGF-1.
- Stremming et al. LR3 IGF-1 and organ-specific growth in fetal sheep. Front Physiol. 2022. — a study using LR3 IGF-1 to examine muscle myoblast proliferation and organ growth.
- White et al. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. Am J Physiol Endocrinol Metab. 2025. — important counter-evidence that IGF-1 LR3’s growth effects are not universal.
- Effects of GH or IGF-1 use on oxidative stress in bodybuilders (PMC). — a study directly examining IGF-1-using bodybuilders.
Reference & Background
- Wikipedia: IGF-1 LR3 — structure (83 amino acids), potency, and half-life reference.
- Wikipedia: Insulin-like growth factor 1 — background on native IGF-1, its role in growth, and the GH/IGF-1 axis.
- Wikipedia: IGF-1 receptor (IGF-1R) — the tyrosine-kinase receptor IGF-1 LR3 activates.
- Wikipedia: Mecasermin (Increlex) — the FDA-approved recombinant IGF-1 drug, for context on approved IGF-1 use.
- DrugBank: Mecasermin — pharmacology reference for recombinant IGF-1.
Full disclaimer: This guide is educational only and is not medical advice. IGF-1 LR3 is not approved for human use anywhere and is sold as a research chemical; buying, possessing, or using it may be restricted where you live, and it is prohibited in competitive sport. Dosing, cycle, stacking, and forum information reflects what is reported in research and community discussion, not a recommendation to do any of it. IGF-1 is mitogenic and its long-term safety in humans is unstudied. Always consult a qualified healthcare professional before considering any peptide or hormone.